ClinicalTrials.govrestricted
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
ClinicalTrials.gov study NCT04287829. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
ShareScore
32/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 12
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 8